Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Raises PT on The Medicines Company

Share:
Related MDCO
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says
The Medicines Company Announces FDA Approval of KENGREAL as an Adjunct to Percutaneous Coronary Intervention for Reducing Thrombotic Events
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th! (Seeking Alpha)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Neutral rating on The Medicines Company (NASDAQ: MDCO), and raised its price target from $26.00 to $30.00.

BofA Merrill Lynch noted, “On Tuesday, MDCO announced results from its phase 3 PHOENIX trial that showed its reversible IV anti-platelet drug cangrelor achieved statistical significance in improvement of ischemic events vs. clopidogrel in patients undergoing percutaneous coronary intervention (PCI). We had viewed this outcome as likely given the favorable interim read and the scrutinized trial design following the failure of its previous phase 3 trial (CHAMPION). We view achievement of statistical significance as a major step forward and have increased our probability of approval to 80% (from 60%), and model peak risk-adjusted US sales of ~$210mn in 2019 ($140mn previously). However, we remain cautious on cangrelor's peak penetration rate in the PCI market (20%). Our PO increased to $30 (from $28) as a result of our model changes.”

The Medicines Company closed on Tuesday at $28.83.

Latest Ratings for MDCO

DateFirmActionFromTo
May 2015Leerink SwannMaintainsOutperform
May 2015JP MorganMaintainsOverweight
Apr 2015CitigroupMaintainsNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters